Cocrystal Pharma, Inc. (COCP)
Nasdaq · Healthcare · Biotechnology
$1.11−4.31%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $21.4M
- 52-week range
- $0.76 – $2.03
- 52-week change
- −4.96%
- EPS (trailing)
- −$0.76
Fiscal year to Dec 2025
- Net income
- −$8.8M
- Diluted EPS
- −$0.78
- Free cash flow
- −$8.2M
From the company’s annual report on SEC EDGAR.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp.
Headquarters: Bothell, United States · 10 employees · cocrystalpharma.com